SLC15A2 作为前列腺癌的新奇预后生物标志物和标
Wenjun Yin1,2, Pingkaiqi He1, Zhihao Zou2,3
1Department of Urology, Minimally Invasive Surgery Center, The First Affiliated Hospital of Guangzhou Medical University, Guangdong Key Laboratory of Urology, Guangzhou Institute of Urology, Guangzhou, P.R. China.
Anticancer research
|December 31, 2024
概括
溶性载体家族15成员2 (SLC15A2) 是前列腺癌 (PCa) 的一个有前途的预后生物标志物. 减少SLC15A2表达与糟糕的结果相关,为风险分层和个性化PCa治疗提供了潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 溶性载体家族15成员2 (SLC15A2) 在细胞信号传递中起作用,但其在前列腺癌 (PCa) 中的功能尚不清楚.
- 调查SLC15A2的预后价值对于理解PCa进展至关重要.
研究的目的:
- 确定SLC15A2在前列腺癌 (PCa) 的预后意义.
- 探索PCa.中的SLC15A2的生物功能和治疗向.
主要方法:
- 在PCa患者中对SLC15A2表达和生存的多中心队列分析.
- 进行了体外验证,基因组丰富,突变,甲基化和药物标预测分析.
主要成果:
- 在PCa组织中,SLC15A2的表达显著较低,并且与降低生存率和增加复发率有关.
- 抑制SLC15A2增强了PCa细胞的增殖和迁移;其下调与TP53突变和DNA高甲基化有关.
- 鲁卡卡里布被确定为一种潜在的治疗剂,在PCa.中向SLC15A2的治疗剂.
结论:
- SLC15A2是PCa的有价值的预后生物标志物,有助于生物化学复发风险分层.
- 这些发现支持基于SLC15A2状态的PCa个性化治疗策略的开发.
相关概念视频
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:39lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K